RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA
Clinical trials for RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough leukemia in patients with RUNX1 mutation
Disease control TerminatedThis study tested two drugs, omacetaxine and venetoclax, in 24 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to treatment. All participants had a specific genetic change called RUNX1. The goal was to find the best dose and see if t…
Matched conditions: RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
Promising combo for tough leukemias hits roadblock: trial ends early
Disease control TerminatedThis study tested a combination of two drugs, venetoclax and decitabine, in 235 people with certain blood cancers (like acute myeloid leukemia and high-risk myelodysplastic syndrome) that either came back or didn't respond to prior treatment, or in older adults who couldn't handl…
Matched conditions: RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:17 UTC